ClinicalTrials.gg
CompletedNCT04466566Updated Oct 28, 2026Results posted

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

A Phase 3 interventional study of Saline and Exendin-9,39 in Healthy, sponsored by Adrian Vella. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Adrian Vella · Phase 3, Interventional, and Basic science

How we know

Updated Oct 28, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study to find out how genetic variations in GLP1R alter insulin secretion, in the fasting state and when blood sugars levels are elevated.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Adrian Vella is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 40 nondiabetic subjects will be recruited.
  • 20 subjects with the AA or AG genotype at rs3765467 and remainder will have the GG genotype.
  • Individuals encompassing the age span of 18-65 years.

Exclusion criteria

Exclusion Criteria:

  • Individuals under 18 and over 65 years of age.
05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Placebo comparator
    Saline

    Saline will be infused during the study

    Other: Saline

  • Active comparator
    Exendin-9,39

    Exendin-9,39 will be infused during the study

    Biological: Exendin-9,39

  • Active comparator
    Liraglutide

    Liraglutide will be infused during the study

    Biological: Liraglutide

Interventions

  • OtherSaline

    Saline will serve as the control

  • BiologicalAvexitideStudies of AvexitideAvexitide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Exendin-9,39 will block the GLP-1 receptor

  • BiologicalLiraglutide

    Liraglutide will serve as the GLP-1 receptor agonist/stimulator

06

What researchers measure

Primary outcomes

  1. Average Insulin Secretion in Response to Hyperglycemia

    Insulin secretion was estimated from C-peptide concentrations using the deconvolution method which incorporates c-peptide kinetics, and the subject's age, body surface area, body mass index, and diabetes status. A hyperglycemic clamp will be used which allows the glucose to be maintained at 160mg/dL (9mmol/L). C-peptide concentrations were drawn every 10 minutes from -30 minutes to 180 minutes, and the insulin secretion at 180 minutes was reported.

    Time frame: insulin secretion rate at the end of the hyperglycemic clamp i.e.: 180 minutes

Secondary outcomes

  1. Change in Glucagon Secretion Rate Measured by Immunoassay

    The Glucagon secretion rate during fasting (0 minutes) and at the end of the hyperglycemic clamp (180 minutes).

    Time frame: 0 Minutes, 180 Minutes

07

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneSaline Exendin VictozaSaline Victoza ExendinExendin Saline VictozaExendin Victoza SalineVictoza Saline ExendinVictoza Exendin Saline
Started726113
Completed616102
Not completed110011
Withdrew: Lost to follow-up110001
Withdrew: Loss of iv000010

Outcome measures

PrimaryAverage Insulin Secretion in Response to Hyperglycemia

Insulin secretion was estimated from C-peptide concentrations using the deconvolution method which incorporates c-peptide kinetics, and the subject's age, body surface area, body mass index, and diabetes status. A hyperglycemic clamp will be used which allows the glucose to be maintained at 160mg/dL (9mmol/L). C-peptide concentrations were drawn every 10 minutes from -30 minutes to 180 minutes, and the insulin secretion at 180 minutes was reported.

Time frame:
insulin secretion rate at the end of the hyperglycemic clamp i.e.: 180 minutes
Reported as:
Mean · μIU/mL
Average Insulin Secretion in Response to Hyperglycemia
μIU/mLSalineExendin-9, 39Liraglutide
AG Genotype17 ± 213 ± 1154 ± 12
AA Genotype33 ± 358 ± 23542 ± 143
GG Genotype23 ± 316 ± 2184 ± 17
SecondaryChange in Glucagon Secretion Rate Measured by Immunoassay

The Glucagon secretion rate during fasting (0 minutes) and at the end of the hyperglycemic clamp (180 minutes).

Time frame:
0 Minutes, 180 Minutes
Reported as:
Mean · pmol/min
Change in Glucagon Secretion Rate Measured by Immunoassay
pmol/minSalineExendin-9,39Liraglutide
AG Genotype 0 Minutes20.6 ± 5.522.8 ± 4.622.1 ± 3.4
AA Genotype 0 Minutes36.4 ± 7.957.7 ± 15.346.0 ± 6.4
GG Genotype 0 Minutes18.7 ± 1.319.3 ± 2.517.2 ± 1.9
AG Genotype 180 Minutes5.8 ± 0.16.4 ± 0.66.3 ± 0.1
AA Genotype 180 Minutes6.6 ± 0.16.5 ± 0.16.3 ± 0.1
GG Genotype 180 Minutes6.1 ± 0.16.0 ± 0.16.0 ± 0.2

Adverse events

Collected over Adverse events were collected from the time of informed consent through study completion, approximately 16 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saline0/17 (0%)0/17 (0%)4/17 (23.5%)
Exendin-9,390/17 (0%)0/17 (0%)3/17 (17.6%)
Liraglutide0/17 (0%)1/17 (5.9%)7/17 (41.2%)
Most frequent serious events
Most frequent serious events
EventSalineExendin-9,39Liraglutide
Nausea/Emesis/Sweating DiaphoresisGastrointestinal disorders0/170/171/17
Most frequent other events
Most frequent other events
EventSalineExendin-9,39Liraglutide
HypoglycemiaMetabolism and nutrition disorders0/171/173/17
Nausea/VomitingGastrointestinal disorders2/171/172/17
Flushed/Hot/DiaphoreticSkin and subcutaneous tissue disorders1/171/172/17
HeadacheNervous system disorders2/170/171/17
Asymptomatic hypoglycemiaMetabolism and nutrition disorders0/170/171/17
Lightheaded/Shaky/Pale/SweatyNervous system disorders1/170/170/17
HypotensionVascular disorders0/171/170/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Saline, Exednin-9, 39 and Liraglutide
Mean46.8 ± 3.9
Sex: Female, Male
Sex: Female, Male(Participants)Saline, Exednin-9, 39 and Liraglutide
Female14
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Saline, Exednin-9, 39 and Liraglutide
Hispanic or Latino1
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Saline, Exednin-9, 39 and Liraglutide
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Saline, Exednin-9, 39 and Liraglutide
United States17
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Sep 2025, 35 months.

Results were first posted in Oct 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 10, 2020
StartActual
Oct 17, 2022
Primary completionActual
Sep 30, 2025
CompletionActual
Dec 30, 2025
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Eligibility
Minimum age 25 Years→18 Years; 2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Edited20 subjects with the AA or AG genotype at rs3765467 and remainder will have the GG genotype.
  • EditedIndividuals encompassing the age span of 2518-65 years.
Exclusion criteria
  • EditedIndividuals under 2518 and over 65 years of age.
Oct 28, 2026
Interventions
Added Biological: Liraglutide. Arms added: Liraglutide
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Insulin secretion quantified using the minimal model to generate an index of beta-cell responsivity (Φ)Now Average Insulin Secretion in Response to HyperglycemiaTime frame: This will be calculated from the 0-180 minute data of the study → insulin secretion rate at the end of the hyperglycemic clamp i.e.: 180 minutes
Oct 28, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Glucagon secretion measuredSecretion Rate Measured by immunoassayImmunoassayTime frame: This will be averaged over the 0-180 minute data of the study → 0 Minutes, 180 Minutes
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Eligibility Minimum age 25 Years→18 Years; 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Edited20 subjects with the AA or AG genotype at rs3765467 and remainder will have the GG genotype.
    • EditedIndividuals encompassing the age span of 2518-65 years.
    Exclusion criteria
    • EditedIndividuals under 2518 and over 65 years of age.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Insulin secretion quantified using the minimal model to generate an index of beta-cell responsivity (Φ)Now Average Insulin Secretion in Response to HyperglycemiaTime frame: This will be calculated from the 0-180 minute data of the study → insulin secretion rate at the end of the hyperglycemic clamp i.e.: 180 minutes
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Glucagon secretion measuredSecretion Rate Measured by immunoassayImmunoassayTime frame: This will be averaged over the 0-180 minute data of the study → 0 Minutes, 180 Minutes
    Interventions Added Biological: Liraglutide. Arms added: Liraglutide
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04466566
Lead sponsor
Adrian Vella
Responsible party
Adrian Vella (Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Jul 10, 2020
Start date
Oct 17, 2022
Primary completion
Sep 30, 2025
Completion
Dec 30, 2025
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Adrian Vella, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avexitide · Liraglutide

Start the discussion